Neuromuscular Blocking Agents for Acute Respiratory Distress Syndrome

Overview

Journal J Crit Care

Specialty Critical Care

Date 2018 Nov 7

PMID 30396789

Citations 9

Authors

Heather Torbic

Abhijit Duggal

Affiliations

Soon will be listed here.

Abstract

Acute respiratory distress syndrome (ARDS) is an acute inflammatory process that impairs the ability of the lungs to oxygenate thereby resulting in respiratory failure. Treatment of ARDS is often a multimodal approach using both nonpharmacologic and pharmacologic treatment strategies in addition to trying to reverse the underlying cause of ARDS. Neuromuscular blocking agents (NMBAs) have been prescribed to patients with ARDS as they are thought to decrease inflammation, oxygen consumption, and cardiac output and help facilitate ventilator synchrony. NMBAs have only been evaluated in patients with early, severe ARDS in three multicenter, randomized, controlled trials (n = 432), but have resulted in decreased inflammation and improved oxygenation, ventilator-free days, and mortality. Despite reports of NMBAs being associated with adverse effects like postparalytic quadriparesis, myopathy, and prolonged recovery, these effects have not been seen in patients receiving short courses of NMBAs for ARDS. A large multicenter, prospective, randomized, placebo-controlled trial is ongoing to confirm benefit of NMBAs in early, severe ARDS when adjusting for limitations of the previous studies. The current available literature suggests that 48 h of NMBA therapy in patients with early, severe ARDS improves mortality, without resulting in additional patient harm.

Citing Articles

Atracurium Versus Cisatracurium in the Treatment of Acute Respiratory Distress Syndrome.

Carabetta S, Allen B, Cannon C, Hailu K, Johnson T J Pharm Technol. 2023; 39(5):212-217.

PMID: 37745727 PMC: 10515971. DOI: 10.1177/87551225231194031.

Research Progress on Phenotypic Classification of Acute Respiratory Distress Syndrome: A Narrative Review.

Wu L, Lei Q, Gao Z, Zhang W Int J Gen Med. 2023; 15:8767-8774.

PMID: 36601648 PMC: 9807128. DOI: 10.2147/IJGM.S391969.

Using sequence clustering to identify clinically relevant subphenotypes in patients with COVID-19 admitted to the intensive care unit.

Oh W, Jayaraman P, Sawant A, Chan L, Levin M, Charney A J Am Med Inform Assoc. 2022; 29(3):489-499.

PMID: 35092685 PMC: 8800515. DOI: 10.1093/jamia/ocab252.

Obesity as a Risk Factor for Failure to Wean from ECMO: A Systematic Review and Meta-Analysis.

Zaidi S, Saleem K Can Respir J. 2021; 2021:9967357.

PMID: 34093924 PMC: 8164539. DOI: 10.1155/2021/9967357.

The Implementation of Protocol-Based Utilization of Neuromuscular Blocking Agent Using Clinical Variables in Acute Respiratory Distress Syndrome Patients.

Hadique S, Badami V, Forte M, Kovacic N, Umer A, Shigle A Crit Care Explor. 2021; 3(3):e0371.

PMID: 33786447 PMC: 7994065. DOI: 10.1097/CCE.0000000000000371.

References

Torbic H, Bauer S, Personett H, Dzierba A, Stollings J, Ryder L . Perceived safety and efficacy of neuromuscular blockers for acute respiratory distress syndrome among medical intensive care unit practitioners: A multicenter survey. J Crit Care. 2016; 38:278-283. DOI: 10.1016/j.jcrc.2016.11.040. View

Hubmayr R, Abel M, REHDER K . Physiologic approach to mechanical ventilation. Crit Care Med. 1990; 18(1):103-13. DOI: 10.1097/00003246-199001000-00022. View

Forel J, Roch A, Marin V, Michelet P, Demory D, Blache J . Neuromuscular blocking agents decrease inflammatory response in patients presenting with acute respiratory distress syndrome. Crit Care Med. 2006; 34(11):2749-57. DOI: 10.1097/01.CCM.0000239435.87433.0D. View

Paton W . Mode of action of neuromuscular blocking agents. Br J Anaesth. 1956; 28(10):470-80. DOI: 10.1093/bja/28.10.470. View

Greenberg S, Vender J . The use of neuromuscular blocking agents in the ICU: where are we now?. Crit Care Med. 2013; 41(5):1332-44. DOI: 10.1097/CCM.0b013e31828ce07c. View

Loper K, Butler S, Nessly M, Wild L . Paralyzed with pain: the need for education. Pain. 1989; 37(3):315-316. DOI: 10.1016/0304-3959(89)90196-6. View

Price D, Kenyon N, Stollenwerk N . A fresh look at paralytics in the critically ill: real promise and real concern. Ann Intensive Care. 2012; 2(1):43. PMC: 3519794. DOI: 10.1186/2110-5820-2-43. View

Meduri G, Headley A, Golden E, J Carson S, Umberger R, Kelso T . Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA. 1998; 280(2):159-65. DOI: 10.1001/jama.280.2.159. View

Rhoney D, Murry K . National survey of the use of sedating drugs, neuromuscular blocking agents, and reversal agents in the intensive care unit. J Intensive Care Med. 2004; 18(3):139-45. DOI: 10.1177/0885066603251200. View

10.

Weber-Carstens S, Deja M, Koch S, Spranger J, Bubser F, Wernecke K . Risk factors in critical illness myopathy during the early course of critical illness: a prospective observational study. Crit Care. 2010; 14(3):R119. PMC: 2911767. DOI: 10.1186/cc9074. View

11.

Rosenberg J, Eisen L . Eye care in the intensive care unit: narrative review and meta-analysis. Crit Care Med. 2008; 36(12):3151-5. DOI: 10.1097/CCM.0b013e31818f0ee7. View

12.

Moore L, Kramer C, Delcoix-Lopes S, Modrykamien A . Comparison of Cisatracurium Versus Atracurium in Early ARDS. Respir Care. 2017; 62(7):947-952. DOI: 10.4187/respcare.05102. View

13.

McCullough M, Kholdani C, Zamanian R . Prevention of Deep Vein Thrombosis and Pulmonary Embolism in High-Risk Medical Patients. Clin Chest Med. 2018; 39(3):483-492. DOI: 10.1016/j.ccm.2018.04.002. View

14.

Bellani G, Laffey J, Pham T, Fan E, Brochard L, Esteban A . Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. JAMA. 2016; 315(8):788-800. DOI: 10.1001/jama.2016.0291. View

15.

Griffiths R, Hall J . Intensive care unit-acquired weakness. Crit Care Med. 2010; 38(3):779-87. DOI: 10.1097/CCM.0b013e3181cc4b53. View

16.

Huang D, Angus D, Moss M, Thompson B, Ferguson N, Ginde A . Design and Rationale of the Reevaluation of Systemic Early Neuromuscular Blockade Trial for Acute Respiratory Distress Syndrome. Ann Am Thorac Soc. 2016; 14(1):124-133. PMC: 5291480. DOI: 10.1513/AnnalsATS.201608-629OT. View

17.

Villar J, Blanco J, Kacmarek R . Current incidence and outcome of the acute respiratory distress syndrome. Curr Opin Crit Care. 2015; 22(1):1-6. DOI: 10.1097/MCC.0000000000000266. View

18.

Inoue S, Kawaguchi M, Sasaoka N, Hirai K, Furuya H . Effects of neuromuscular block on systemic and cerebral hemodynamics and bispectral index during moderate or deep sedation in critically ill patients. Intensive Care Med. 2006; 32(3):391-7. DOI: 10.1007/s00134-005-0031-3. View

19.

Strange C, Vaughan L, Franklin C, Johnson J . Comparison of train-of-four and best clinical assessment during continuous paralysis. Am J Respir Crit Care Med. 1997; 156(5):1556-61. DOI: 10.1164/ajrccm.156.5.9701079. View

20.

Sottile P, Kiser T, Burnham E, Ho P, Allen R, Vandivier R . An Observational Study of the Efficacy of Cisatracurium Compared with Vecuronium in Patients with or at Risk for Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2017; 197(7):897-904. PMC: 6020402. DOI: 10.1164/rccm.201706-1132OC. View